Could a bladder drug calm POTS? new trial aims to find out
NCT ID NCT07585513
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether mirabegron, a drug currently used for overactive bladder, can reduce symptoms of Postural Orthostatic Tachycardia Syndrome (POTS). Thirty-six adults with confirmed POTS will receive either mirabegron or a placebo. The main goal is to see if the drug lowers the number of symptom episodes patients report each day.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mirabegron
What this could lead to
If it works, this could point toward a new treatment option to reduce daily symptoms for people with POTS.
What could go wrong
This is a small, early-phase trial with only 36 participants. The drug may not prove more effective than placebo, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••